Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Inclusion Criteria: All subjects:： * Signing the informed consent forms； * 18 years to 65 years (inclusive)； * Body mass index should be between 18 and 30 kg/m2 (inclusive)； * No medication was used before screening，or stable medication for 4 weeks. Normal liver function： * Clinical laboratory tests during the screening period were normal，or the abnormality has no clinical significance. Hepatic impaired subjects: * Child-Pugh Classification score clinically determined as mild or moderate hepatic impairment. * Liver damage due to primary liver disease. Exclusion Criteria: All subjects: * Subject known or suspected of being sensitive to the study drugs or its ingredient； Normal liver function： * Previous history of liver function impairment, or physical examination and laboratory examination at screening indicated the presence or possibility of liver function impairment. * Hepatitis B surface antigen (HBsAg) positive or Anti-hepatitis C virus (HCV) antibody or hepatitis C core antigen positive within 3 months prior to administration. Hepatic impaired subjects: * Suspected or diagnosed as liver cancer or with other malignant tumors; * Drug induced liver injury，acute liver injury，liver transplantation history. * Subjects with hepatic failure,or severe complications caused by Hepatocirrhosis.